What this trial means for you
This study is opening soon at 2 US sites. It's studying see the official record for chronic kidney disease, type 2 diabetes.
What participants typically get: study medication (or placebo, if the trial uses one) and study-related medical care at no cost, plus close monitoring. Compensation for time and travel varies by study — ask the site. Note that in many trials you can't choose your treatment group, and some participants receive a placebo.
The study, in the sponsor's words
The goal of this pragmatic randomized clinical trial is to determine whether an Epic-based clinician notification increases initiation of guideline-directed cardio-kidney-metabolic (CKM) therapies in adults with type 2 diabetes and confirmed albuminuria. The main question it aims to answer is: • Does an Epic clinician notification improve initiation of guideline-directed CKM therapies compared with usual care? Researchers will compare an Epic in-basket clinician notification strategy with usual care. In the intervention arm, the treating clinician will receive an Epic notification identifying confirmed albuminuria and potential eligibility for guideline-directed CKM therapies using existing electronic health record (EHR) data. Participants in the usual care arm will receive standard clinical care without notification.
Can you join? The exact criteria
Below is the verbatim eligibility text from the registry — bring it to your doctor; it's written for clinicians, and your own clinician is the right person to interpret it with you.
Full eligibility criteria (for you and your doctor)
Inclusion Criteria * Adults aged ≥18 years * Diagnosis of type 2 diabetes mellitus * Receiving outpatient care within Baylor Scott \& White Health * At least 1 outpatient encounter within the preceding 12 months * Confirmed albuminuria (UACR \>30 mg/g) * Eligible for one or more guideline-directed CKM therapies based on - prespecified clinical criteria and EHR review Exclusion Criteria: * Type 1 diabetes mellitus * Contraindication or documented intolerance to all eligible guideline-directed CKM therapies * Advanced kidney dysfunction below recommended initiation thresholds for SGLT2i or finerenone * Hyperkalemia or elevated baseline serum potassium precluding safe therapy initiation * Contraindicated drug interactions (e.g., strong CYP3A inhibitors with finerenone) * Other guideline- or labeling-based contraindications to therapy initiation
Study sites by state
Texas
- Baylor Scott and White Health — Dallas
- Baylor Scott and White, Advanced Heart Care — Plano
View the official record on ClinicalTrials.gov →
Follow this trial
Get an email when our monthly digest covers enrollment changes and results for trials like this one.
Newsletter signup launches soon. (Site owner: set PUBLIC_BUTTONDOWN_USERNAME in
.env to activate this form.)